Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	1692
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	1481
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	1346
Retracted	847
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	537
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	450
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	374
Efficacy and safety of infliximab in patients with autoimmune hepatitis	293
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	227
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	215
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	205
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	205
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	196
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	188
Cover Image	174
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	170
Late-Breaking Abstracts	169
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	168
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	167
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	162
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	160
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	157
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	157
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	154
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	140

REPLY:	135
Reply	131
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	131
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	130
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	129
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	124
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	124
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	122
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	122
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	121
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	121
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	120
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	118
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	118
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	117
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	113
Access to technology to support telehealth in areas without specialty care for liver disease	111
Regulatory role and translational potential of CCL11 in liver fibrosis	108
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	107
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	105
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	105
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	105
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	103
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	103
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	102
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	98
	98
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	98
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	97
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	96
	96
Instructions to Authors	94
Letter to the editor	94
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	93
Healthy peribiliary glands are necessary for successful liver transplantation	92
Erratum	92
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	86
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	86
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	86
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	84
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	83
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	83
Letter to the Editor: Overlooking the important factor: Hypoxia	82
Reply	82
REPLY:	81
In vivo imaging of calcium dynamics in zebrafish hepatocytes	80
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	80
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	79
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	79
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	78

Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	78
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	77
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	77
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	76
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	76
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	76
Letter to the Editor	75
Much more needed in natural history of Alagille syndrome	74
Hepatology Highlights	74
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	73
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	73
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	72
To Be or Not to Be	72
With Alcohol as the Fuel, COVID Is the Match	72
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	72
Endpoints and New Options for Treatment of Chronic Hepatitis D	71
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	70
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	69
The international quest for the imaging diagnosis of liver cancer	68
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	68
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	68
Therapeutic manipulation of the microbiome in liver disease	67
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	67
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	67
Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?	66
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	66
The digital determinants of liver disease	66
Genes that fit just right: Unzipping the genome of fatty liver disease	66
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	66
A strategy of vascular‐targeted therapy for liver fibrosis	65
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	65
Fontan‐associated liver disease	64
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	64
Immunobiology of primary sclerosing cholangitis	62
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	62
NAFLD‐related hepatocellular carcinoma: The growing challenge	62
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	62
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	61
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	61
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	61
Metabolic dysfunction-associated steatotic liver disease and the heart	61
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	61
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	60
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	60
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease	60
The clot and the complicated consult	59
Enoxacin Up‐Regulates MicroRNA Biogenesis and Down‐Regulates Cytotoxic CD8 T‐Cell Function in Autoimmune Cholangitis	59
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	59
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	59
Hepatology Highlights	58
Reply	58
REPLY:	58
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	58
Reply	57
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	57
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	57
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	56
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality	56
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study	56
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	55
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	55
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	55
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	54
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	54
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	54
Manuscript best practices: Takeaways from a community conversation	53
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	53
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	53
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	53
Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion	53
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	53
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	52
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	52
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	52
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	51
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	51
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	51
Reply	51
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	51
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	50

HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	50
Pathway to global elimination of hepatitis B: HBV cure is just the first step	50
Reply	50
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	50
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	50
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	50
Reply	50
Oral Abstracts	50
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	49
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	49
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	49
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	48
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	48
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	48
In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood	48
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	48
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	48
Future directions in acute liver failure	47
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	47
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	47
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via non-canonical phosphorylation	47
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	46
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	46
Table of contents	46
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	46
Cover Image	46
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab	45
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	45
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	45
Table of contents	45
Cover Image	44
Reply	44
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	44
Masthead	44
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	43
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	43
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	43
Masthead	43
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	42
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	42
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	42
Telehealth interventions in patients with chronic liver diseases: A systematic review	42
Prognostic significance of mild ascites in patients with cirrhosis	42
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation	42
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	42
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	42
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	42
Reply	41
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	41
Letter to the editor: HuR in liver homeostasis	41
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	41
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	41
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	40
Imaging for better responses to immunotherapy in hepatocellular carcinoma	40
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	40
Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto‐sinusoidal Vascular Liver Disease	40
Presenting the new incoming editorial team for hepatology: Team members and perspectives	40
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	39
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	39
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	39
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	39
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	39
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	39
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	39
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	39
Predicting liver outcomes with biomarker monitoring in MASLD	39
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	39
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	38
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	38
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	38
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	38
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway	38
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	38
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	38
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis	38
Intrahepatic cholangiocarcinoma PANoptosidy	38
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	37
Fructose‐1,6‐Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis	37
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	37
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	37
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma	37
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	37
The evolving role of liver sinusoidal endothelial cells in liver health and disease	37
A global action agenda for turning the tide on fatty liver disease	36
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	36
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	36
Retraction: Altered store operated calcium entry increases cyclic 3′,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective	36
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	36
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	36
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	36
Category Index	36
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	36
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	36
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	36
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	36